Skip to main content

Table 4 Efficacy outcomes, reported by arm

From: EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Event Arm A, 100 mg/m2 (n = 79) Arm B, 125 mg/m2 (n = 79)
Median EFS, mos (90% CI) 8.2 (5.9–8.9)
6.2 (5.8–8.4)#
8.3 (6.2–9.7)
6.4 (5.8–7.7)#
Median EFS pts 75+, mos (90% CI) 8.3 (5.7–8.9)
5.9 (5.1–8.3)#
8.2 (3.5–10.9)
6.9 (5.5–8.3)#
Median PFS, mos (95% CI) 8.3 (5.9–10.5) 8.8 (7.4–10.3)
Median OS, mos (95% CI) 22.4 (17.0–35.6) 20.7 (16.8–28.6)
Best overall response*, n (%) n = 60 n = 65
CR 4 (7) 1 (2)
PR 20 (33) 26 (40)
SD 24 (40) 18 (28)
PD 9 (15) 14 (21)
NE 3 (5) 6 (9)
  1. CI confidence interval, CR complete response, EFS event-free survival, mos months, NE not evaluable, OS overall survival, PFS progression-free survival, PD progressive disease, PR partial response, SD stable disease
  2. #Based on central review
  3. *Patients with measurable disease